Cebranopadol as a Novel Promising Agent for the Treatment of Pain. (PubMed, Molecules) - Jul 11, 2022 - "The compound acts on the mu opioid receptor and the nociceptin/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management."
Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry
|